For decades, families of people with Alzheimer’s disease faced a grim choice when agitation set in: accept antipsychotic medications that carried a black-box warning for increased mortality risk, or struggle with untreated behavioral symptoms that made daily care almost impossible. In April 2026, the FDA approved Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride)—the first medication specifically designed to treat agitation in Alzheimer’s dementia without being an antipsychotic. Available since summer 2026, this approval represents a genuine shift in how doctors can approach one of dementia’s most challenging symptoms. Auvelity works by combining two existing drugs—a cough suppressant and an antidepressant—in a formulation that produces a synergistic effect neither drug achieves alone.
The significance cannot be overstated: before 2026, people with Alzheimer’s disease had only one FDA-approved medication with a primary indication for agitation: brexpiprazole (Rexulti), and even that belongs to the antipsychotic class. For caregivers, this approval means options have suddenly expanded after decades of limited choices. What makes Auvelity fundamentally different is what it does not carry—a black box warning about increased mortality risk in older adults with dementia-related psychosis. All atypical antipsychotics carry this warning, plus additional FDA cautions about stroke and sedation. This safety profile distinction has meaningful implications for family discussions with neurologists and geriatricians, especially when an older person with dementia has heart disease, prior stroke, or other conditions that make antipsychotic use risky.
Table of Contents
- What Is Agitation in Dementia and Why Has It Been So Hard to Treat?
- The Problem With Antipsychotics: Why Doctors Have Avoided Better Options Until Now
- How Auvelity Works: A Different Approach to Calming Dementia Agitation
- Is Auvelity Right for Your Loved One? Comparing Treatment Options
- What About Side Effects and Safety Concerns?
- Other Non-Antipsychotic Alternatives Under Investigation
- What Families and Caregivers Need to Know Before Discussing Auvelity With a Doctor
What Is Agitation in Dementia and Why Has It Been So Hard to Treat?
Agitation in dementia is not simple restlessness or mood irritability. It encompasses hitting, kicking, verbal hostility, pacing, resisting care, and explosive reactions to minor frustrations—behaviors that emerge as cognitive decline progresses and the person loses the ability to communicate needs or understand their surroundings. A person with moderate Alzheimer’s may become physically aggressive during bathing, refuse meals, or attempt to leave a care facility multiple times per day. For families, these behaviors are often more distressing than memory loss itself, because they shatter the remaining relationship and make daily care unsafe for both the person with dementia and their caregivers. Doctors have struggled to treat agitation because the underlying cause involves multiple brain pathways simultaneously.
Dementia damages not only memory centers but also areas controlling emotion regulation, impulse control, and the interpretation of threat. Antipsychotics dampen these overactive brain signals broadly, but in doing so, they also slow thinking, suppress movement, and increase the risk of stroke and death—side effects that led many geriatricians to avoid them except as a last resort. The need for a more targeted approach has been evident for years, but developing one has proven difficult. This is where Auvelity’s mechanism offers something different. Rather than broadly suppressing dopamine activity across the brain, the combination of dextromethorphan and bupropion targets specific neural systems involved in agitation regulation without producing the sedation, rigidity, or metabolic effects associated with antipsychotics. In clinical trials leading to FDA approval, the drug demonstrated meaningful reductions in agitation symptoms—meaningful enough that the FDA determined it warranted approval for this specific indication.
The Problem With Antipsychotics: Why Doctors Have Avoided Better Options Until Now
For the past two decades, antipsychotic medications have been prescribed off-label for dementia agitation despite clear evidence of harm. The FDA does not approve any antipsychotic specifically for dementia-related agitation (with the exception of brexpiprazole, approved in 2015). Instead, doctors prescribed risperidone, olanzapine, quetiapine, and aripiprazole based on clinical experience and small studies, knowing they carried significant risks. The black box warning exists because of mortality data from multiple randomized controlled trials. Older adults with dementia who took atypical antipsychotics for behavioral symptoms had higher rates of death from cardiovascular events, stroke, and infection compared to those who received placebo. The increased mortality risk is not small—studies showed an approximately 1.5 to 2-fold increase in death rates over periods of weeks to months. For a family contemplating whether to give their 82-year-old mother with Alzheimer’s an antipsychotic to control agitation, this warning creates genuine moral and medical uncertainty.
Some families decided to accept the behavioral symptoms rather than introduce a medication linked to earlier death. Beyond mortality, antipsychotics carry practical downsides that degrade quality of life. Sedation is common, leaving the person with dementia sleeping much of the day. Movement disorders such as tardive dyskinesia (involuntary facial grimacing and body movements) can emerge, sometimes irreversibly. Weight gain and metabolic changes increase diabetes risk. Falls become more common because of sedation and balance problems, paradoxically making care more dangerous, not safer. For frail older adults, these side effects often outweigh the benefit of reduced agitation. This risk-benefit calculation has left many geriatricians reaching for antipsychotics only when behavior becomes dangerous and no alternatives exist.
How Auvelity Works: A Different Approach to Calming Dementia Agitation
Understanding Auvelity’s mechanism requires stepping back from traditional antipsychotic thinking. Dextromethorphan is a cough suppressant familiar to anyone who has taken over-the-counter cold medicine. Bupropion is an antidepressant that increases dopamine and norepinephrine availability in the brain. Neither drug alone has been shown to effectively treat dementia agitation. The formulation Auvelity combines them specifically so the bupropion boosts dopamine in pathways related to mood and motivation, while the dextromethorphan modulates a completely different system—the NMDA receptor—that plays a role in emotional regulation and agitation. Together, they produce an effect greater than either alone. This synergistic approach is not entirely novel in pharmacology, but it is novel for dementia treatment.
The FDA’s approval of Auvelity represents recognition that agitation is not a single-pathway problem and that targeting multiple systems simultaneously, if done carefully, can achieve symptom control without the collateral damage of antipsychotics. The clinical trial data supporting approval showed that people taking Auvelity experienced significantly greater reductions in agitation compared to those on placebo, with a safety profile that did not include the mortality concerns that plague antipsychotics. One important limitation: Auvelity is not a fast-acting medication. It typically takes 1 to 2 weeks to show benefit, and optimal effect may take 4 weeks or more. This matters for families and care facilities managing acute behavioral crises. If someone is actively violent or posing immediate danger, Auvelity cannot be started and expected to help in hours. Short-term de-escalation still may require PRN (as-needed) medications or other interventions, then Auvelity can be introduced as a longer-term solution to reduce the overall frequency and severity of agitated episodes.
Is Auvelity Right for Your Loved One? Comparing Treatment Options
Deciding whether Auvelity makes sense requires understanding what alternatives exist and their relative merits. For someone with mild agitation that does not pose safety risks, behavioral interventions—reducing triggers, modifying the environment, providing meaningful activities—should always be the first step. Antipsychotics and Auvelity are not first-line treatments; they are for agitation severe enough to warrant medication. When medication is needed, the choice now sits between Auvelity and the antipsychotics (primarily brexpiprazole, risperidone, or quetiapine). Auvelity’s main advantage is the absence of black box mortality warning and lower risk of sedation and movement disorders. The main disadvantage is that it has only recently been approved, so long-term safety data (beyond the trials leading to approval) does not yet exist.
Many neurologists and geriatricians are still in the phase of learning to use it. Some family members and care facilities may face resistance to using a “new” medication when older, more familiar options exist. A concrete example illustrates the tradeoff. Consider an 80-year-old man with moderate Alzheimer’s disease, a history of atrial fibrillation (irregular heartbeat), and worsening agitation that interferes with his ability to tolerate care. An antipsychotic like risperidone might control the agitation but increases his already-elevated stroke risk and mortality risk, a particularly poor tradeoff given his cardiac history. Auvelity, with no black box warning and no established increase in cardiovascular events, might be chosen instead. Conversely, for someone in a brief behavioral crisis requiring immediate symptom control, an as-needed sedating medication might be used short-term, with a transition to Auvelity planned for longer-term management once the acute crisis resolves.
What About Side Effects and Safety Concerns?
Auvelity is not side-effect-free. Common side effects in trials included nausea, dizziness, dry mouth, and constipation—none severe, but all requiring monitoring and possible dose adjustment. Unlike antipsychotics, Auvelity did not produce significant sedation, weight gain, or movement disorders in trial participants. However, because it has only recently been approved, rare side effects may not yet be apparent. This is why ongoing monitoring and communication with the prescribing doctor remains essential. One specific concern for caregivers: bupropion (part of Auvelity) is known to lower seizure threshold in some people, meaning it can increase seizure risk. For someone with dementia who has had a prior seizure or has a seizure disorder, Auvelity may not be appropriate, and other options should be considered.
Additionally, because both components interact with other medications, drug-drug interactions are possible. A person taking Auvelity who starts a new medication should have that interaction checked with their pharmacist or doctor. Another practical consideration is cost and access. Auvelity is a brand-name medication, so it may be expensive without insurance coverage. Generic versions are unlikely to become available for several years. Some insurance plans may require prior authorization before covering it, meaning the prescribing doctor must justify the choice to the insurance company before the medication can be dispensed. This bureaucratic step can delay access, particularly frustrating when someone’s family is eager to try a promising new option.
Other Non-Antipsychotic Alternatives Under Investigation
Auvelity is not the only non-antipsychotic approach to agitation. Research has shown that citalopram, a selective serotonin reuptake inhibitor (SSRI) antidepressant, reduces agitation in Alzheimer’s disease better than placebo in randomized trials. Citalopram works through a completely different mechanism—by increasing serotonin availability—and does not carry black box warnings or significant cognitive side effects. However, citalopram is less specific to agitation than Auvelity; it is often used for depression or anxiety in dementia but is not FDA-approved specifically for agitation.
Guanfacine, an older blood pressure medication, is also being studied as a potential treatment for agitation in dementia. It works by dampening noradrenaline activity in specific brain regions and shows promise in preliminary studies with fewer side effects than antipsychotics. If future trials are positive, guanfacine could offer another non-antipsychotic option, particularly valuable because it is generic and inexpensive. However, as of now, guanfacine remains experimental for dementia agitation and is not FDA-approved for this indication.
What Families and Caregivers Need to Know Before Discussing Auvelity With a Doctor
If you are caring for someone with dementia and agitation is becoming a problem, bringing Auvelity into a conversation with their neurologist or geriatrician is reasonable. The approval is recent enough that not all doctors have prescribed it yet, so you may need to educate yourself on the basics to advocate effectively. Come prepared with a clear description of the agitation—what triggers it, how often it happens, whether it poses safety risks, and what non-medication strategies have already been tried. Be aware that Auvelity works best when started early, before agitation becomes severe and entrenched. It is also important to understand that starting a new medication requires patience; expecting improvement within days will lead to disappointment.
Realistic expectations are that after 4 weeks on Auvelity, episodes of agitation may become less frequent or intense, but the person may not be “cured” of agitation altogether. Ongoing monitoring, possible dose adjustments, and continued use of behavioral strategies remain necessary. Finally, do not assume that Auvelity will work for everyone. Some people respond excellently; others have minimal response. If Auvelity is tried and proves ineffective after an adequate trial (typically 4 to 6 weeks at therapeutic dose), alternative approaches can be considered. The existence of Auvelity now means that when antipsychotics are considered, there is a documented safer alternative that was tried first—an important shift in the standard of care for dementia agitation.
- —
